BtX Has Arrived in Europe - Are You Ready?

What is it? What does it do? Why opportunity depends on getting the evaluation right, and what medical device innovators and manufacturers should do with it right now to accelerate development and commercial opportunities.

With the publication of MDCG 2025-9 in December 2025, the EU introduced a more structured way to identify and support so-called Breakthrough Devices (BtX) under both the MDR and IVDR. If you work with innovative medical technologies, this is a significant development to examine.

In simple terms, it is the first time there's a clear framework aimed specifically at helping truly innovative devices get recognized. This has been a long time coming. For manufacturers trying to bring highly innovative products to market, especially something addressing a life-threatening condition or an unmet medical need, this is significant, especially in a system that has often been difficult to navigate for novel products.

That said, BtX is NOT the EU equivalent of an accelerated approval pathway like the FDA's Breakthrough Devices Program. It does not create a separate fast-track pathway, and it does NOT reduce the underlying standard for demonstrating safety and performance. Manufacturers still need to build a robust evidence package.

So, while BtX is not a shortcut, it can offer a more supportive framework for certain truly novel devices, particularly by enabling earlier interaction and more structured planning.

What is BtX?

In simple terms, BtX is a designation for devices, both medical devices and IVDs, that are genuinely innovative and expected to make a real clinical difference.

To qualify, a device must meet two criteria at the same time.

✓ It must be novel. Your device needs to bring something substantially different to the table such as a new technology, a meaningfully different clinical or procedural approach, or a novel use in practice. The guidance is clear: incremental improvements over existing solutions are unlikely to qualify.

✓ It must be expected to make a meaningful clinical impact. Novelty alone is not enough. Your device must also be expected to provide a meaningful clinical benefit for patients or populations affected by life-threatening or irreversibly debilitating conditions. That benefit may come from outperforming existing options or addressing an unmet need where meaningful alternatives do not exist.

What does BtX designation get you?

BtX does not create a separate approval route, but the designation can offer several practical advantages.

• Recognition as a breakthrough innovator. Formal designation may help validate the significance of your innovation internally and externally, including in discussions with investors or strategic partners.
  

• Flexibility in evidence generation. In practice, that can mean less clinical evidence is needed upfront at the time of registration if patient safety is demonstrated, where some confirmatory evidence is generated (and presented) post-market substantially accelerating your commercialization pathway and revenue generation.
  

• Earlier, more meaningful regulatory engagement and guidance de-risks development. This has high potential to de-risk your path to market by clarifying expectations, improving regulatory alignment and reducing late-stage regulatory roadblocks or surprises and associated delays.
  

• Post-market data becomes more important. Instead of front-loading all your evidence, there's more room to build your case with real-world data after your device is on the market. This makes PMCF and real-world evidence planning more important from the start.

How to acquire BtX designation.

Alongside the BtX framework, the EMA has launched a pilot program that provides expert input for free during the early implementation period. This support is available both to manufacturers and notified bodies, and it’s meant to help you navigate BtX more effectively. In practice that may include early advice on BtX qualification likelihood and guidance on how to apply the MDCG recommendations in practice. BtX designations are proceeded through filling a formal request for an expert panel opinion EMA BtX pilot program. The BtX Pilot evidence dossier compiles technical, clinical and state of the art justification showing unmet medical need expected clinical benefits and why alternatives are insufficient. Panels evaluate novelty, clinical impact, and evidence; they may request clarifications before issuing an opinion. If the expert panel supports the request, the device is designated BtX, enabling priority interactions with notified bodies.

What is the timeline?

The pilot kicked off on 28 April 2026, and is being rolled out in phases, subject to available resources.

Phase 1 (already underway) - This phase is limited to Class III devices, and Class IIb active devices that administer or remove a medicinal product. Submissions for this phase are now closed, and EMA is currently reviewing a small number of selected applications through 31 July 2026.

Phase 2 (starting early 2027) - In this phase, the EMA plans to expand both designation requests and advice to all classes of medical devices, broadening access and benefit potential for manufacturers.-

Phase 3 (expected mid–to-late 2027) - Finally, the scope expands to include IVDs.

If you think your new medical device or IVD is a candidate for BtX designation, start with these 3 things.

1. Pressure-test whether you really qualify. Start by assessing your device against the BtX criteria. Can you clearly explain what makes it truly novel? Can you support the clinical impact with more than a high-level claim? Quantify the benefit where possible, identify where your evidence is still weak (those gaps will matter later), and prepare for structured dialogue with a Notified Body.

2. Get your evidence strategy in shape early. BtX does not lower the bar, but it may well change the timing and sequencing of evidence generation to your advantage. Start by building a solid integrated evidence plan now. What do you need pre-market vs post-market? Where can you realistically rely on post-market data? What are your biggest evidence risks? For lean teams, this is perhaps the most important planning questions to answer well. Your goal is simple: avoid surprises when you engage with regulators.

3. Build BtX into your overall strategy. BtX should not sit in a regulatory silo. If your device may qualify, the implications extend across regulatory strategy, clinical development, preclinical work, and commercial activities including integrated evidece planning. For smaller companies, BtX only adds value if it is built into the larger development roadmap.

For BtX opportunity optimization, evaluate early, plan strategically.  

BtX may open the door to meaningful opportunities for truly innovative devices, but only if the evaluation is done well from the start. That means confirming fit early, understanding where the evidence gaps are, and shaping a regulatory strategy that supports the broader development plan. If BtX may be relevant to your product, get in touch with our EU regulatory team to pressure-test the opportunity and determine the best path forward. Veranex positions its EU MDR and IVDR support around strategic, practical implementation and documentation planning; exactly the kind of early assessment this requires.

Contact us for comprehensive BtX evaluation and advancement support. We can tell you where you stand, develop your regulatory strategy, and execute the technical documentation, performance evaluation, and clinical work needed to make the most of the opportunity.  

About the authors: 

Silvia Anghel, PhD, has a unique combination of scientific research expertise and extensive industry experience in the field of in vitro diagnostics (IVD). Her distinguished background includes research conducted in prestigious laboratories across Canada and Switzerland, focusing on oncology, metabolism-related disorders – including cardiovascular diseases –, and gastroenterology. She has more than 15 years of industry experience, managing projects related to the development, manufacturing, regulatory compliance and quality management of IVD devices. At Veranex, Silvia guides manufacturers through regulatory pathways and performance evaluation strategies, leveraging her comprehensive understanding of product lifecycles from development through commercialization. She provides strategic guidance in quality management system implementation, technical documentation development, and critical negotiations with Competent Authorities and Notified Bodies, making her an invaluable resource for companies navigating the complex IVD regulatory landscape.